S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for S100 Calcium Binding Protein A9 (S100A9) ,etc. by FLIA (Flow Luminescence Immunoassay)
MRP14; MIF; 60B8AG; CFAG; NIF; CAGB; CGLB; L1AG; P14; Calgranulin B; Migration inhibitory factor-related protein 14; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain
（注：單次混測多因子不超過8個指標(biāo) ）
- 編號ULMB793Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.98-1000pg/mL
- 靈敏度最小可檢測劑量小于等于0.327 pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價格 ¥ 1245 ¥ 1293 ¥ 1365 ¥ 1460 ¥ 1556 ¥ 1700 ¥ 1915 ¥ 2394 添加到價格計算器 計算器
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 89-97 | 93 |
| EDTA plasma(n=5) | 85-94 | 90 |
| heparin plasma(n=5) | 78-105 | 91 |
| sodium citrate plasma(n=5) | 78-99 | 87 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-92% | 86-97% | 91-99% | 94-101% |
| EDTA plasma(n=5) | 80-90% | 87-96% | 82-90% | 81-105% |
| heparin plasma(n=5) | 79-89% | 92-105% | 79-101% | 86-101% |
| sodium citrate plasma(n=5) | 92-105% | 98-105% | 82-101% | 81-90% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UEPB793Hu61 | S100鈣結(jié)合蛋白A9(S100A9)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPB793Hu01 | S100鈣結(jié)合蛋白A9(S100A9)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPB793Hu01 | S100鈣結(jié)合蛋白A9(S100A9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB793Hu01 | S100鈣結(jié)合蛋白A9(S100A9)多克隆抗體 | WB; IHC; ICC/IF |
| ULAB793Hu81 | S100鈣結(jié)合蛋白A9(S100A9)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAB793Hu71 | S100鈣結(jié)合蛋白A9(S100A9)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAB793Hu29 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體 | WB |
| UMAB793Hu22 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體 | WB; IHC |
| UMAB793Hu21 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體 | WB; IHC |
| UMAB793Hu23 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體 | WB |
| UMAB793Hu27 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體 | WB; IHC; ICC/IF |
| UMAB793Hu24 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體 | WB; IHC |
| UMAB793Hu25 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體 | WB; IHC |
| ULAB793Hu82 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAB793Hu72 | S100鈣結(jié)合蛋白A9(S100A9)單克隆抗體(生物素標(biāo)記) | WB |
| USEB793Hu | S100鈣結(jié)合蛋白A9(S100A9)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB793Hu | S100鈣結(jié)合蛋白A9(S100A9)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSB793Hu01 | S100鈣結(jié)合蛋白A9(S100A9)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| J. Proteome Res. | Differential Proteomic Analysis Distinguishes Tissue Repair Biomarker Signatures in Wound Exudates Obtained from Normal Healing and Chronic Wounds [Pubmed: source] |
| Biochemical and Biophysical Research Communications | High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice [ScienceDirect: S0006291X1200352X] |
| PLoS One. | Proteins with Altered Levels in Plasma from Glioblastoma Patients as Revealed by iTRAQ-Based Quantitative Proteomic Analysis [PubMed: 23029420] |
| Mainz | Identifizierung neuer potentieller Biomarker für das Kolonkarzinom sowie dessen Vorstufen [Info:Source] |
| PLOS ONE | Susceptibility to COPD: Differential Proteomic Profiling after Acute Smoking [Pubmed:25036363] |
| the faseb journal | Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation [PubMed: 25934702] |
| Sci Rep.? | S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine [pmc:PMC4810364] |
| Journal?of?Alzheimer's?Disease | Proteomics?Analysis?of?Blood?Serums?from?Alzheimer's?Disease?Patients?Using?iTRAQ?LabelingTechnology. [pubmed:27911324] |
| International journal of molecular sciences | Immune Modulating Topical S100A8/A9 Inhibits Growth of Pseudomonas aeruginosa and Mitigates Biofilm Infection in Chronic Wounds. [pubmed:28672877] |
| Gastroenterology | Tu1938-Micronutrients Assessment in Patients with Cirrhosis [10.1016:S0016-5085(18)33544-3] |
| Gastroenterology | Tu1942-PI3K/AKT-Mediated Upregulation of C7 Inhibits Colorectal Cancer Proliferation and Metastasis [10.1016:S0016-5085(18)33544-5] |
| Journal of Biological Chemistry | Signaling between pancreatic β-cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation [Pubmed:29496993] |
| Cancer?Management and?Research | The role of calgranulin B gene on the biological behavior of squamous cervical cancer in vitro and in vivo [Pubmed:29497331] |
| European?review for?medical?and pharmacological?sciences | S100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα. [Pubmed:29949169] |
| Estudio de células inmunosupresoras y biomarcadores circulantes en carcinoma renal [] | |
| Lung | Mass Spectrometry Analysis of the Exhaled Breath Condensate and Proposal of Dermcidin and S100A9 as Possible Markers for Lung Cancer Prognosis [Pubmed: 31115649] |
| 中國醫(yī)藥導(dǎo)報 | 降鈣素原, 超敏C 反應(yīng)蛋白, 紅細(xì)胞沉降率及S100A9 對肺結(jié)核合并肺部細(xì)菌感染的影響 [] |
| scandinavian journal of clinical & laboratory investigation | Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study [Pubmed: 31856598] |
| PLoS One | Adverse reproductive effects of S100A9 on bovine sperm and early embryonic development in vitro [Pubmed: 31945120] |
| Sci Rep | Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate [34045609] |
| university of copenhagen | Adjunctive S100A8/A9 Immunomodulation Hinders Cipro fl oxacin Resistance in [] |
